Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Netazepide, a Gastrin/CCK2 Receptor Antagonist, on Esomeprazole-induced Increases in Circulating Gastrin and Chromogranin A, and on Esomeprazole Withdrawal in Healthy Subjects

NCT02620696 is registered in ClinicalTrials.gov with Trio Medicines Ltd. as lead sponsor.

NCT NCT02620696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02620696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Netazepide, a Gastrin/CCK2 Receptor Antagonist, on Esomeprazole-induced Increases in Circulating Gastrin and Chromogranin A, and on Esomeprazole Withdrawal in Healthy Subjects
Lead sponsor
Trio Medicines Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2009
Completion date
September 30, 2010
Enrollment
48 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dyspepsia, ecl-cell hyperplasia, parietal-cell hyperplasia, rebound hyperacidity